The 72 kDa Type IV Collagenase pipeline drugs market research report outlays comprehensive information on the 72 kDa Type IV Collagenase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the 72 kDa Type IV Collagenase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology, Central Nervous System, and Cardiovascular which include the indications Melanoma, Metastatic Melanoma, Epilepsy, Neuropathic Pain (Neuralgia), and Diastolic Heart Failure (HFpEF). It also reviews key players involved in 72 kDa Type IV Collagenase targeted therapeutics development with respective active and dormant or discontinued products.

The 72 kDa Type IV Collagenase pipeline targets constitutes close to six molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in and Preclinical stages are and 4 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.

72 kDa Type IV Collagenase overview

72 kDa type IV collagenase or matrix metalloproteinase-2 (MMP-2) and gelatinase A is an enzyme encoded by the MMP2 gene. It is an Ubiquitinous metalloproteinase. It is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. It plays an important role in myocardial cell death pathways. It contributes to myocardial oxidative stress by regulating the activity of GSK3beta.

For a complete picture of 72 kDa Type IV Collagenase’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.